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Purpose. Dysfunction of matriptase-2 can be involved in iron regulatory disorder via downregulation of hepcidin expression. In the
present study, we investigated the effects of 3-amidinophenylalanine-derivedmatriptase inhibitors on porcine hepatic inflammatory
cellmodels.Methods. Hepatocyte-Kupffer cell cocultures (ratio of 2 : 1 and 6 : 1) were treatedwith four structurally relatedmatriptase
inhibitors at 50𝜇M. Cell cytotoxicity and relative expressions of IL-6 and IL-8 and the levels of hepcidin were determined by MTS
andporcine-specific ELISA.The extracellularH
2
O
2
contentswere analyzed byAmplexRedmethod.Results.Matriptase inhibitors at
50 𝜇M for 24 h did not increase cell death rate.The elevated ROS production observed after short-term application of inhibitor MI-
441 could be correlatedwith lowered hepcidin expression.MI-460 could significantly enhance hepcidin levels in the supernatants of
cocultures (by 62.21± 26.8% in hepatocyte-Kupffer cell, 2 : 1, and by 42.6± 14.3% in hepatocyte-Kupffer cell, 6 : 1, cocultures, resp.).
No significant changes were found in IL-6 and IL-8 levels in cocultures exposed to matriptase inhibitors. Conclusions. Based on
in vitro findings, administration of MI-460 via modulation of hepcidin expression without cytotoxic and oxidative stress inducing
properties might be a reliable alternative to treat iron overload in human and veterinary clinical practice.
1. Introduction
Several type II transmembrane serine proteases (TTSPs) are
associated with cell surface proteolysis and can be divided
into four subfamilies such as human airway trypsin-like
protease (HAT)/differentially expressed in squamous cell
carcinoma (DESC), hepsin/transmembrane protease, serine 2
(TMPRSS), corin, and matriptase (MT). They also play
crucial roles in tightly regulated physiological processes [1].
Expression of matriptase-1 (MT-1) is not limited to any parti-
cular organ [2], whereas matriptase-2 (MT-2) mainly accu-
mulates in the liver in both human and mouse, which reveals
its tissue-specific functions [3].
Consequently, deregulated MT-1 and MT-2 activities
have been linked to various pathological conditions. It was
reported that MT-1 overproduction in osteoarthritis could
promote the induction of cartilage destruction [4]. MT-1
activity is also involved in tumorigenesis of various cancer
types and promotes the progression ofmalignant transforma-
tions via cleavage and activation of substrates like hepatocyte
growth factor/scatter factor [5–7].
MT-2, also known as TMPRSS6, is highly expressed
in the liver and it negatively affects the production of the
hepatic hormone hepcidin, the main regulator of systemic
iron homeostasis through the interaction with the bone mor-
phogenetic protein coreceptor hemojuvelin (HJV) [8–10].
After binding, MT-2 degrades and reduces cell surface HJV
and prevents hepcidin from being expressed via induction
through bone morphogenetic protein 6 (BMP6) [9]. Active
HJV facilitates transcription of hepcidin responsible for iron
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transport to the bloodstream.This mechanism is impaired in
iron-refractory iron deficiency anaemia due to the hepcidin-
dependent cellular iron accumulation and loss of MT-2
proteolytic function as a result of genetic mutation [11, 12].
The elevated production rate of hepcidin triggered by
high iron level can lower the iron absorption from the
duodenum and reduce the iron release from the iron storages
thus stabilizing the finely adjusted physiological iron concen-
tration [13, 14]. The hepcidin secretion in the liver can be
elevated due to the infections and inflammatory disorders,
which can be facilitated by the proximity of pathogens-
sensing Kupffer cells, to which the body reacts with iron
deficiency and anaemic conditions consequently. This host
defensive mechanism in response to infectious diseases can
provide significant reduction in the amount of iron essen-
tial for the survival of the microbes. In case of sustained
iron deficiency, the hepatocytes produce less hepcidin; thus
iron concentration increases again in the blood circulation.
Other influencing factors such as bleeding, application of
erythropoietin (EPO), and overproduction of reactive oxygen
species (ROS) can also modulate the hepcidin expression
significantly [15].
MT-1 and MT-2 are belonging to the TTSPs having an
extracellular trypsin-like serine protease domain at the C-
terminus, which can be blocked by 3-amidinophenylalanine-
derived inhibitors. The most potent inhibitors contain
N-terminal dichloro- or dimethoxy-biphenyl-3-sulphonyl
group and inhibitMT-1 in the lowone-digit nanomolar range,
whereas MT-2 is less potently inhibited [16]. As mentioned
above, MT-2 plays an important regulatory role in iron
homeostasis; thus this enzyme may act as a pharmacolog-
ical target in the treatment of the systemic iron overload
(hemochromatosis). This approach seems to be supported
by the fact that lack of functional MT-2 can result in high
hepatic hepcidin expression, which results in iron-deficiency
anaemia [8].
Appropriately established cell models can be used to
mimic in vivo pathophysiological conditions such as inflamed
liver thereby enabling the replacement of some animal exper-
iments. A porcine primary hepatocyte-Kupffer cell coculture
with variable ratios of cell types has been previously devel-
oped and characterized [17]. In this model, hepatocytes were
cocultured with Kupffer cells in the ratio of 6 : 1 (HepK6) and
2 : 1 (HepK2) in an attempt to mimic hepatic inflammation
with different severity. This system seems to be a proper
tool to investigate certain molecular mechanisms within the
inflamed liver, such as to assess the possible effects of MT-2
inhibition on the regulation of iron homeostasis in hepatic
inflammation.
The main aim of this research was to explore the pos-
sible relationship between coculture model of hepatocytes
and Kupffer cells of swine liver and selected drug candi-
dates. In our study, the regulatory properties of four potent
3-amidinophenylalanine-derived MT-1 inhibitors (MI-432,
MI-441, MI-460, and MI-461), which also possess a mod-
erate inhibitory potency against MT-2, were elucidated in
vitro in hepatic inflammatory models HepK2 and HepK6
cocultures to determine how MT-1/MT-2 modulation affects
cell viability and physiological redox status, possibly being in
connection with hepcidin production. The analysis of
changes in the hepcidin expression was a prerequisite for
exploring a link between the effect of MT-1/MT-2 suppres-
sion and iron homeostatic processes. As hepcidin-mediated
disturbances in iron metabolism are often coupled to an
inflammatory response, therefore, the expressions of the
proinflammatory cytokines, IL-6 and IL-8, were also moni-
tored.
2. Materials and Methods
2.1. Isolation and Cultivation of Hepatocytes and Kupffer Cells.
Hepatocyte-Kupffer cell cocultures were freshly prepared
from 15 kg weighing male pigs of the Hungarian Large White
breed (obtained from Dunahyb Ltd., Fadd, Hungary) [17].
Briefly, hepatocytes and Kupffer cells were isolated by multi-
step perfusion and collagenase-mediated enzymatic digestion
of the caudate lobe of the liver. Hepatocytes were sedimented
and purified by a revised low-speed centrifugation (50×g,
75 s); Kupffer cells were obtained from the supernatants by
Percoll gradient centrifugation (500×g, 20min).The viability
of both cell types was assessed by trypan blue exclusion test
and revealed more than 90% viable cells in all cases.
As nonparenchymal cells can attach faster, Kupffer cells
were seeded first on previously collagen-coated (Type I,
10 𝜇g/cm2) 12-well Costar TC6 cell culture dishes (Corn-
ing International, Corning, NY, USA) and on 96-well
microplates, the latter being used for MTS assays on cell
viability. Hepatocytes and Kupffer cells were seeded on the
same dishes in the appropriate cell ratio 6 : 1 (hepatocyte to
Kupffer cell) for modelling moderate and 2 : 1 for more severe
inflammation.Theprepared cocultures were incubated under
humid atmosphere at 37∘C using 10% CO
2
, and culture
medium was exchanged 6 h after seeding. Culturing of
cells was performed in Williams medium E, supplemented
with 10000 IU/mL penicillin, 10mg/mL streptomycin, 2mM
glutamine, 10% FBS, and 0.2 IU/mL insulin. Fetal bovine
serum (FBS) was applied during the first 24 h of culturing.
Confluent monolayer cocultures were obtained after 24 h
incubation (Figures 1(a) and 1(b)), being suitable for the
further examinations.
2.2. Chemical Structures of Applied Matriptase Inhibitors.
The structures of the used 3-amidinophenylalanine-derived
inhibitors and their previously published 𝐾
𝑖
values against
MT-1 and MT-2 [16] are summarized in Table 1. The com-
pounds MI-432 andMI-441 are dibasic inhibitors containing
a C-terminal 2-aminoethylpiperidide group, whereas the
analogues MI-460 and 461 are more hydrophobic monobasic
derivatives.
2.3. Exposure of HepK2 and HepK6 Cells to Matriptase
Inhibitors. Stock solutions of the inhibitors were prepared
with a concentration of 10mM and kept at −20∘C. Before
treatment, confluent HepK2 and HepK6 cocultures were
washed twice with plain medium. The solutions of the
inhibitors in phenol red free Williams medium E at 50𝜇M
were prepared freshly prior to each experiment from the stock
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Figure 1: Giemsa staining of cocultures. HepK cell cocultures with the cell ratio of 2 : 1 (a) and 6 : 1 (b) (hepatocyte to Kupffer cell) after 24 h
culturing following Giemsa staining (200x magnification). Scale bar = 50 𝜇m.
Table 1: Chemical structures and𝐾
𝑖
values of the used 3-amidinophenylalanine-derived inhibitors towardsmatriptase-1 (MT-1),matriptase-2
(MT-2), and thrombin.
Number Structure 𝐾𝑖 (𝜇M)
MT-1 MT-2 Thrombin
MI-432
S
H
N
N
O
O O
HN
ClCl
NH2
NH2 0.002 0.11 0.02
MI-441
S
H
N
N
O
O O
HN
Cl
Cl
NH2
NH2 0.011 0.21 0.02
MI-460
S
H
N
N
O
O O
HN
O O NH
N
H
O
NH2
CH3 CH3
CH3 0.0018 0.18 0.0008
MI-461
S
H
N
N
O
O O
HN
ClCl N
H
N
H
O
NH2
CH3
0.0009 0.073 0.0002
solutions. After incubation of the inhibitor for 2 h (in case of
H
2
O
2
, IL-6 and IL-8, and hepcidin assays) or 24 h (in case
of cell viability tests), the cocultures were washed twice
with plain medium before being subjected to the subsequent
procedures.
2.4. MTS Assay for Cell Viability. Influence of matriptase
inhibitors in phenol red free Williams medium E on the
viability of HepK2 and HepK6 cocultures was tested. Mono-
layer cocultures, grown on a 96-well plate for 24 h, were
incubated with matriptase inhibitors for 24 h in treated
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Figure 2: Lack of cytotoxic effects of matriptase inhibitors. (a) 24 h incubation of HepK2 cells with MI-432, MI-441, MI-460, or MI-461
at 50 𝜇M. Values represent average relative absorbance values of produced MTS formazan in metabolically active cells expressed in control
values ± SEMs. No significant differences were found between control and cocultures exposed to matriptase inhibitors (𝑛 = 4). (b) HepK6
cocultures were treated with MI-432, MI-441, MI-460, or MI-461 at 50𝜇M for 24 h. Relative absorbance values expressed in control values ±
SEMs are indicated. No significant differences were found between control and treated cocultures (𝑛 = 4).
groups. The control cells were incubated only with phenol
red free Williams medium E. After removal of the medium
and washing the cells 3-fold with phosphate-buffered saline
(PBS), 20𝜇L of CellTiter 96 aqueous one solution prolifera-
tion assay (MTS, Promega, Bioscience, Budapest, Hungary)
containing tetrazolium compound and an electron coupling
reagent, phenazine ethosulfate, was pipetted into each well of
the 96-well assay plate containing the samples in 100 𝜇L of
culture medium. The plate was incubated with dye for 2 h.
Viability of HepK2 and HepK6 cocultures was measured at
490 nm using EZ Read Biochrom 400 microplate reader.
2.5. Extracellular H
2
O
2
Measurement by the Amplex Red
Method. Fluorescence ROSmeasurement of cell supernatant
was based on the detection of H
2
O
2
using the Amplex Red
HydrogenPeroxideAssayKit (Invitrogen,Molecular Probes).
In the presence of horseradish peroxidase (HRP), Amplex
Red reacts with H
2
O
2
in a 1 : 1 stoichiometry producing a
highly fluorescent resorufin [18]. Following the exposure of
cocultures to matriptase inhibitors (50𝜇M, 2 h), the H
2
O
2
concentrations in the medium were determined 6 h after
completion of the treatment using a working solution of
100 𝜇MAmplexRed and0.2U/mLHRP.After 30min incuba-
tion with the dye at room temperature, the quantitative H
2
O
2
contents were measured using a Victor X2 2030 fluorometer
(𝜆ex = 560 nm; 𝜆em = 590 nm).
2.6. Cytokine Measurements by Enzyme-Linked Immunosor-
bent Assay. After 2 h inhibitor treatment (50𝜇M), HepK2
andHepK6 cocultures were incubated in the medium for 6 h.
Culture media were collected, centrifuged (245×g for 10min
at room temperature), and diluted to measure the IL-6 and
IL-8 levels.
Changes in IL-6 and IL-8 concentrations relative to those
in controls were determined by porcine-specific IL-6 (Sigma-
Aldrich, St. Louis, MO, USA) and IL-8 (Abcam, Cambridge,
UK) ELISA kits according to the manufacturer’s instruc-
tions. The absorbance values were detected at 450 nm using
EZ Read Biochrom 400 microplate reader (Biochrom Ltd.,
UK).
2.7. Hepcidin ELISA Measurements. Porcine ELISA kit for
hepcidin was obtained from Cloud-Clone Corp. (Houston,
Texas, USA), employing the competitive inhibition enzyme
immunoassay technique. After 2 h inhibitor treatment
(50 𝜇M), the HepK2 and HepK6 cell cocultures were
incubated for 6 h and then the culture media were collected,
centrifuged (1000×g for 20min at room temperature), and
diluted in PBS.The assay procedurewas performed according
to themanufacturer’s guideline.After addition of the 3,3󸀠,5,5󸀠-
tetramethylbenzidine (TMB) substrate solution for 15min,
the intensity of color developed is reverse proportional to
the concentration of hepcidin in the sample. The absorbance
values were detected at 450 nm using a EZ Read Biochrom
400 microplate reader (Biochrom Ltd., UK).
2.8. Statistical Analysis. For statistical evaluation R 2.11.1
software package (2010)was applied. Statistical significance of
differences was assessed with one-sample Student’s 𝑡-tests for
assessment of relative values. Differences between absolute
means were evaluated by one-way analysis of variance (one-
way ANOVA) with post hoc Tukey test, where data were
of normal distribution and homogeneity of variances was
confirmed. Differences were considered significant if the 𝑝
value was <0.05 marked with ∗ (∗∗𝑝 < 0.01).
3. Results
3.1. Assessment of Cell Viability after Matriptase Inhibition.
Cell cytotoxicity assays were performed to evaluate if the used
inhibitors at 50𝜇M concentration can cause significant cell
death in HepK2 and HepK6 cocultures. It was found that
the selected inhibitors can be used at 50𝜇M concentration
safely for 24 h in HepK2 (Figure 2(a)) and HepK6 cocultures
(Figure 2(b)), and thus this concentration could be applied in
further experiments to characterize the effects of MT-1/MT-2
modulation in in vitro inflammatory hepatic models.
3.2. Matriptase Inhibition-Induced Oxidative Stress. Fluores-
cence intensities of both the control and treated samples were
measured 6 h after a 2 h inhibitor application of matriptase
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Figure 3: Extracellular ROS production of HepK2 and HepK6 cell
cocultures control (Co) or exposed tomatriptase inhibitors (MI-432,
MI-441, MI-460, or MI-461) using Amplex Red method. Results are
expressed as mean values relative to controls ± SEMs. Significant
differences in fluorescence intensities were found between control
and MI-441-treated coculture groups (∗𝑝 < 0.05, 𝑛 = 4, in HepK2
and ∗∗𝑝 < 0.01, 𝑛 = 4, in HepK6 samples).
inhibitors at 50𝜇M. It was found that there was an increase in
the extracellular H
2
O
2
levels (Figure 3) causing a significant
elevation in fluorescence, when inhibitor MI-441 was applied
in HepK2 and HepK6 cocultures (𝑝 = 0.0147 and 𝑝 =
0.00157, resp.). However, no significant perturbations in
redox balance in case of HepK2 and HepK6 cocultures were
observed after treatmentwith the other three inhibitors under
identical conditions.
3.3. Determination of IL-6 and IL-8 Levels in the Supernatants
of Hepk2 and Hepk6 Cocultures. After treatment of HepK2
and HepK6 cell cocultures with matriptase inhibitors at
50𝜇M concentration for 2 h, the potential changes in IL-6
expressions were monitored in the cell supernatants. It was
ascertained that none of the applied inhibitors could induce
elevated production of IL-6 in HepK2 and in HepK6 cells
(Figure 4). The relative absorbance values of IL-8 levels were
also measured to determine the putative changes introduced
by short-term administration of matriptase inhibitors. It was
found that the applied compounds did not cause any signif-
icant alterations in the levels of IL-8 in the supernatants of
HepK2 and HepK6 cocultures compared to those in control
groups (Figure 5).
3.4. Analysis of Hepcidin Levels in the Supernatants of Hepk2
and Hepk6 Cell Cocultures. In HepK2 coculture it was found
that MI-432 and MI-461 at 50 𝜇M for 2 h did not alter
hepcidin levels significantly compared to those of control
samples (𝑝 = 0.6571 and 𝑝 = 0.2006, resp.). However,
matriptase inhibition via application of MI-441 and MI-460
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Figure 4: The effect of matriptase inhibition on IL-6 levels. The
relative IL-6 levels after the HepK2 and HepK6 cell cocultures were
treated with 50 𝜇M MI-432, MI-441, MI-460, and MI-461 for 2 h.
The columns represent average relative absorbance values ± SEMs
(𝑛 = 4). No significant differences were found (𝑝 > 0.05) between
control and matriptase inhibitor-treated groups.
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Figure 5: The effect of matriptase inhibition on IL-8 levels. The
HepK2 and HepK6 cell cocultures were treated with 50 𝜇MMI-432,
MI-441, MI-460, andMI-461 for 2 h.The columns represent average
relative absorbance values± SEMs (𝑛 = 4). No significant differences
were found (𝑝 > 0.05) between control and matriptase inhibitor-
treated groups.
with the same incubation time and concentration has
changed hepcidin levels in different ways. Treatment with
MI-441 has lowered the hepcidin expression by 32.3 ± 12.8%
(𝑝 = 0.0487), whereas it seems that compound MI-460
leads to an upregulation of hepcidin expression by 62.21 ±
26.8% (𝑝 = 0.0368) in the cell supernatants. Similar
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Figure 6: Changes in relative hepcidin levels after matriptase
inhibition. Measurements were performed at 6 h after completion
of 2 h 50 𝜇M MI-432, MI-441, MI-460, or MI-461 treatment. Each
column represents themean relative absorbance values ± SEMs (𝑛 =
3). The asterisk (∗𝑝 < 0.05) shows statistical significances for results
expressed in control percentage.
findings were obtained in HepK6 cell cocultures where MI-
441 administration reduced the hepcidin levels (𝑝 = 0.0387)
by 18.9 ± 3.5% and MI-460 elevated (𝑝 = 0.0114) the
expression of hepcidin by 42.6 ± 14.3%. Application of MI-
432 and MI-461 did not cause significant alterations in the
levels of hepcidin in the supernatants of HepK6 compared to
control samples (𝑝 = 0.8404 and 𝑝 = 0.549, resp.) (Figure 6).
4. Discussion
Physiological plasma and cellular iron concentrations are
provided via strict regulation of critical steps responsible for
iron absorption, transport, storage, and recycling [19]. MT-2
plays a major role in inactivation of HJV thus reducing the
expression of the liver-derived peptide hormone, hepcidin.
Misregulation of hepcidin as a negative regulator of iron
absorption has been found in many diseases such as the
anemia of chronic disease, iron refractory iron deficiency
anemia, cancer, hereditary hemochromatosis, and ineffective
erythropoiesis such as 𝛽-thalassemia [20]. Other factors
such as oxidative stress can also affect hepcidin levels.
Experimental findings support that hepatitis C virus- (HCV-)
induced oxidative stress inhibits hepcidin production offer-
ing a possible explanation for phenomenon of iron loading
when this viral infection occurs [21, 22]. In the prevention
and in the treatment of iron overload hepcidin agonists can
represent therapeutical alternatives against several forms of
the hemochromatosis. Small peptide analogues containing
7–9 amino acids, minihepcidins, were successfully applied
in the regulation of plasma iron concentration in mice
models [23]. It was reported that MT-2 could also affect the
level of produced hepcidin. The loss of the serine protease
domain of MT-2 in different species caused anaemia with
increased hepcidin concentration and with low plasma iron
level due to the reduced iron absorption [9, 10, 19]. MT-
2 mutations in humans or lack of MT-2 in mice resulted
in increased hepcidin expression and iron refractory iron
deficiency anemia [8].
Elevated MT-1 levels could be found in epithelial cancers
suggesting that the dysfunctional matriptase activity may
contribute to tumor development and metastatic events.
MT-1 could trigger the degradation of extracellular matrix
components and intercellular structures thus enabling cell
migration [5]. Moreover, also an aberrant expression of MT-
2 is observed in several forms of cancers such as breast
and prostate cancer [3, 24, 25]. However, more studies
should be conducted to determine the efficacy of MT-1/MT-
2 inhibitors on tumor formation and migration ability of
cancerous cells more precisely based on the approach that
matriptase inhibition might possess beneficial effect against
tumor invasion and metastasis.
Suppression of MT-2 via application of 3-amidinophe-
nylalanine compounds can be an effective pharmacological
option in the effective treatment of hemochromatosis in the
future [8, 12]. The safety of our used inhibitors at 50𝜇M
was confirmed since their 24 h long administration did not
cause any significant changes in cell viability in HepK2 and
HepK6 cocultures. Our data revealed that potent suppression
ofMT-2 activity via 2 h acute treatment of HepK2 andHepK6
cocultures with 50 𝜇M MI-460 could enhance hepcidin
expression to great extent. This suggests that application
of MI-460 can control dysregulated iron metabolism via
increasing hepcidin level present mainly in several forms
of systematic iron overload. In contrast, treatment with
inhibitor MI-441 significantly decreased hepcidin levels,
which might be explained by the fact that hepcidin synthesis
can be affected via oxidative stress and as it was shown by
us that extracellular H
2
O
2
production was elevated by the
addition of MI-441 in both cocultures. The other matriptase
inhibitors (MI-432, MI-460, and MI-461), however, did not
cause any significant changes in extracellular ROSproduction
in these cocultures. In contrast, in our previous studies it
was found that significant ROS release could be detected
mainly after acute administration of MI-432 at 50 𝜇M in
nontumorigenic intestinal porcine epithelial IPEC-J2 cell line
via suppression of MT-1 enzyme activity. These apparent dis-
crepancies between extracellular peroxide productions can be
explained by various responsiveness of different cells such as
IPEC-J2 cells and HepK cocultures towards matriptase inhi-
bition [26]. As MI-432 and MI-461 did not show any acute
effect on hepcidin regulation, thus further studies should be
performed to clarify whether long-term applications of these
compounds possess any impact on pathophysiological iron
conditions.
Hepatic coculture systems consist of primary hepatocytes
and Kupffer cells in a ratio of 6 : 1 and 2 : 1 and they can rep-
resent milder or severe inflammatory states of liver [17, 27].
Kupffer cells can be activated by bacterial endotoxins, which
results in the elevated production of several proinflammatory
cytokines such as IL-6 and IL-8. It was established that this
coculture system can be used to examine chemical-induced
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inflammatory reactions such as shifting in cytokine profile
(IL-6 and TNF-𝛼) as a consequence of acute hepatocellular
toxicity introduced by lipopolysaccharide and trovafloxacin
administration [27]. In our study, 2 h inhibitor administra-
tion did not show any effects on IL-6 and IL-8 levels in
HepK2 and HepK6 cocultures. This suggests that the hepatic
inflammatory response is not influenced by the applied MT-
1/MT-2 inhibitors.
In conclusion, taken together, the fact thatMT-1 andMT-
2 are membrane anchored serine proteases on the cell surface
with relatively convenient accessibility for drugs and the
downregulation of excessive matriptase activities can com-
pensate severe pathological perturbations, further develop-
ment and advanced biomolecular screening of more selective
MT-1 and MT-2 inhibitors can be of high pharmacological
and therapeutical importance.
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